COAG · Hemab Therapeutics Holdings

The thesis

Hemab Therapeutics is modestly more likely than not to beat the S&P 500 over the next three months. Its pivotal trial of sutacimig has started, and the company still guides that its cash lasts into 2029. Updated Factor VII deficiency data at the American Society of Hematology (ASH) meeting on 14 December 2026 test the second use for the drug. A clean safety record as SOLARA, the Phase 3 trial in Glanzmann thrombasthenia, begins dosing is the other half of the case.

The third-quarter report on 10 November 2026 left the case intact. Cash, cash equivalents and marketable securities were $430.2 million at 30 September 2026, against $457.5 million at 30 June 2026, per the company's 8-K. The net loss of $0.58 per share missed the $0.52 estimate, per Benzinga, as research spending rose with the Phase 3 start. Data for HMB-002 in von Willebrand disease moved to the European Association for Haemophilia and Allied Disorders (EAHAD) congress in February 2027.

The shares closed at $39.38 on 12 November 2026, above their 50-day moving average of $37.12, per adjusted daily closes. They are still down 28.3% over three months. The price reflects doubt about the Phase 3 design and safety more than the mid-stage bleed reduction: the shares fell 28.3% over the three months to 12 November 2026 while the trial started on schedule. The rating is Medium because the trial and the cash are in place, while the next hard data arrive only at ASH.

Bullish and bearish views on Hemab Therapeutics Holdings, Inc.

The bull case on Hemab Therapeutics Holdings, Inc. (COAG), in brief: pivotal trial started on schedule. The bear case: clotting remains the central safety question.

Bull case

• Pivotal trial started on schedule. The company's 10 November 2026 release says SOLARA plans to enroll about 75 people aged 12 to 70, with the first participants entering a 24-week run-in in the fourth quarter of 2026. Each then gets 48 weeks of 0.2 mg/kg sutacimig, injected under the skin once a week, and the primary endpoint compares the treated bleed rate on the drug with the run-in rate.
• Regulatory designations support a faster review. Sutacimig holds Fast Track, Orphan Drug and Breakthrough Therapy designations from the Food and Drug Administration (FDA) for Glanzmann thrombasthenia, per coverage of the 9 November 2026 SOLARA announcement.
• Large bleed reduction in mid-stage testing. At the 2026 congress of the International Society on Thrombosis and Haemostasis (ISTH), Hemab reported results from 34 participants at a median of 6.9 months. The mean annualized treated bleed rate fell about 84% in the low-dose weekly group.
• Second indication shows an early signal. The 10 November 2026 release reports that two participants with severe Factor VII deficiency each got a single dose. Prothrombin time, a standard clotting test, shortened by more than 50% in both, and adverse events were low grade and judged unrelated to treatment.
• Cash covers the pivotal program. The company held $430.2 million at 30 September 2026 and guides that cash funds operations into 2029, per the 10 November 2026 8-K. Net cash used in operations was $72.5 million over the first nine months of 2026, per the third-quarter 10-Q.
• Management is in front of investors twice before ASH. The company's 11 November 2026 release schedules fireside chats at the Jefferies Global Healthcare Conference in London on 17 November 2026 and the Evercore Healthcare Conference on 1 December 2026.

Bear case

• Clotting remains the central safety question. Hemab's ISTH release reported three Grade 2 thromboembolic events in the long-term study. SOLARA doses more people for 48 weeks, and an independent data safety monitoring committee must clear dosing before adolescents enroll, per the 10 November 2026 release.
• The FDA wanted a randomized trial. The FDA recommended that Hemab consider a randomized design before the company proceeded with a self-controlled single-arm trial, per the 9 November 2026 release. The third-quarter 10-Q risk factors say regulators may require additional trials, including a randomized controlled trial.
• Spending is rising. Third-quarter research and development spending was $24.6 million, up from $14.6 million a year earlier, and the net loss was $27.3 million, per the 10 November 2026 8-K. Costs climb further as the Phase 3 trial enrolls.
• Second-program data moved later. HMB-002 data are now set for EAHAD in February 2027. The early results are descriptive: 8 of 9 evaluable participants had no treated bleeds in the 28 days after one dose, per the 10 November 2026 release.
• Positive coverage has not lifted the shares. Rodman & Renshaw, J.P. Morgan and LifeSci Capital started coverage with positive ratings between 12 October 2026 and 9 November 2026, and the shares still show a 28.3% three-month decline at the 12 November 2026 close.

Price setup

The shares closed at $39.38 on 12 November 2026. The 50-day moving average stood at $37.12 on the same date, so the price sits above its recent average after a 28.3% fall over three months, per adjusted daily closes. The shares set a then-new one-year high on 6 August 2026, per MarketBeat, and most of the three-month decline came after that high.

The initial public offering (IPO) priced at $18.00 on 30 April 2026. The level the case turns on below the price is the first-day close after the listing. A close beneath it would erase every gain made since the first trading day and would show that the trial start and the cash guidance have the market's support. The quarterly report has passed, so the next scheduled company events are the two investor conferences and the ASH posters.

Catalysts ahead

• 17 November 2026: Fireside chat at the 2026 Jefferies Global Healthcare Conference in London. It is management's first public forum after the third-quarter report and can update SOLARA site activation and the timing of first run-in enrollment.
• 1 December 2026: Fireside chat at the 9th Annual Evercore Healthcare Conference. It is the last scheduled management appearance before the ASH posters and can confirm SOLARA is on track for first participants in the fourth quarter of 2026.
• 13 December 2026: HMB-003 preclinical poster at the ASH Annual Meeting. It shows animal results for the weekly plasmin inhibitor ahead of first human data guided for mid-2027.
• 14 December 2026: Sutacimig Factor VII deficiency poster at the ASH Annual Meeting. Updated results test whether the two-participant prothrombin-time signal holds and supports a second indication for sutacimig.
• ~31 December 2026 (est.): First SOLARA participants enter the 24-week run-in period, guided for the fourth quarter of 2026. It confirms the pivotal trial is enrolling on the timeline the company set in its 10 November 2026 report.
• ~15 February 2027 (est.): HMB-002 VELORA Phase 1/2 data at the EAHAD Congress. It shows whether Hemab's von Willebrand disease program adds value beyond sutacimig.

What would change the view

A daily close below $34.00, the first-day close after the April 2026 IPO, which would erase every gain since listing day. An FDA clinical hold on sutacimig or a drug-related clotting event of Grade 3 or higher would also show the case failing.

The risks this note tracks, each with what would confirm it:

• Clotting events limit sutacimig's use or slow SOLARA. Confirmed by: an FDA clinical hold, or a drug-related thromboembolic event of Grade 3 or higher disclosed in a company update.
• The self-controlled single-arm design weakens the pivotal result in regulators' eyes. Confirmed by: company disclosure of an FDA request to add a randomized control arm, run a second trial or extend SOLARA.
• SOLARA enrollment runs slow in a rare disease. Confirmed by: company guidance moving the first run-in start past the fourth quarter of 2026 or pushing enrollment completion later.
• The early Factor VII signal fades in more patients. Confirmed by: ASH results on 14 December 2026 showing smaller prothrombin-time improvement or shorter Factor VII exposure than the earlier two-participant data.
• Rising Phase 3 spending forces new share issuance. Confirmed by: a follow-on offering announcement or a cut to the runway guidance of into 2029.

What it trades with

Hemab has no product revenue. Its shares move on its own clinical and regulatory news more than on the economy. As a small clinical-stage biotech, it also tends to move with sector-wide shifts in demand for early-stage drug developers. The ASH meeting in December brings out hematology data from many companies at once, so peer results in bleeding disorders can move the shares in the same week as Hemab's posters.